Genetic aspects of epitestosterone formation and androgen disposition: Influence of polymorphisms in CYP17 and UGT2B enzymes

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 477-485

  Schulze, Jenny Jakobsson ^a,b   Lorentzon, Mattias ^c   Ohlsson, Claes ^c   Lundmark, Jonas ^a,b   Roh, Hyung Keun ^d   Rane, Anders ^a,b   Ekström, Lena ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Gachon University College of Medicine   (South Korea)

Author keywords

Androstenediol; CYP17; Doping; Epitestosterone; Gas chromatography mass spectrometry; Glucuronidated androgen metabolites; Men; mRNA; Polymorphisms; Steroid 17 alpha hydroxylase; Testosterone epitestosterone ratio; Uridine diphospho glucuronosyltransferase

Indexed keywords

ANDROGEN; ANDROSTENEDIOL; CYTOCHROME P450 17; EPITESTOSTERONE; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; URIDINE DIPHOSPHOGLUCURONYLTRANSFERASE 2B17;

ADULT; ALLELE; ARTICLE; ENZYME POLYMORPHISM; GAS CHROMATOGRAPHY; GENE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTYPE; HORMONE METABOLISM; HUMAN; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; URIDINE DIPHOSPHOGLUCURONOSYLTRANSFERASE 2B15 GENE; URIDINE DIPHOSPHOGLUCURONOSYLTRANSFERASE 2B17 GENE; URIDINE DIPHOSPHOGLUCURONOSYLTRANSFERASE 2B7 GENE; URINALYSIS;

ADOLESCENT; ADULT; ANDROGENS; ANDROSTANE-3,17-DIOL; BASE SEQUENCE; DNA PRIMERS; DOPING IN SPORTS; EPITESTOSTERONE; GENE DELETION; GENE DOSAGE; GLUCURONOSYLTRANSFERASE; HUMANS; KOREA; LIVER; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; VARIATION (GENETICS);

EID: 44449083711     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fad38a     Document Type: Article

References (39)

1. Donike M, Rauth S, Wolansky A. Reference ranges of urinary endogenous steroids determined by gas chromatography/mass spectrometry. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, editors. Proceedings of the 10th Cologne Workshop on Dope Analysis. Cologne: Sport und Buch Strauß; 1993. pp. 69-86.
2. Ayotte C, Goudreault D, Charlebois A. Testing for natural and synthetic anabolic agents in human urine. J Chromatogr B Biomed Appl 1996; 687:3-25.
3. Park J, Park S, Lho D, Choo HP, Chung B, Yoon C, et al. Drug testing at the 10th Asian Games and 24th Seoul Olympic Games. J Anal Toxicol 1990; 14:66-72.
4. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91:687-693.
5. Dehennin L. On the origin of physiologically high ratios of urinary testosterone to epitestosterone: consequences for reliable detection of testosterone administration by male athletes. J Endocrinol 1994; 142:353-360.
6. Garle M, Ocka R, Palonek E, Bjorkhem I. Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program. Evaluation of 28 cases. J Chromatogr B Biomed Appl 1996; 687:55-59.
7. Kicman AT, Oftebro H, Walker C, Norman N, Cowan DA. Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. Clin Chem 1993; 39:1798-1803.
8. Raynaud E, Audran M, Brun JF, Fedou C, Chanal JL, Orsetti A. False-positive cases in detection of testosterone doping. Lancet 1992; 340:1468-1469.
9. Dehennin L. Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3 beta,17 alpha-diol. J Steroid Biochem Mol Biol 1993; 44:171-177.
10. Weusten JJ, Legemaat G, van der Wouw MP, Smals AG, Kloppenborg PW, Benraad T. The mechanism of the synthesis of 16-androstenes in human testicular homogenates. J Steroid Biochem 1989; 32:689-694.
11. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987; 6:439-448.
12. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3:1873-1876.
13. Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-714.
14. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142:778-787.
15. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Miners JO. The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 2007; 35:363-370.
16. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7:317-325.
17. Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, et al. The UDP Glucuronosyltransferase 2B15 D85Y and 2B17 Deletion Polymorphisms Predict the Glucuronidation Pattern of Androgens and Fat Mass in Men. J Clin Endocrinol Metab 2007; 92:4878-4882.
18. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26:73-77.
19. Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14:473-479.
20. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10:679-685.
21. Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A, Jakobsson J, et al. Sex steroid levels and cortical bone size in young men is associated with a glucuronidation enzyme UGT2B7 polymorphism (H268Y). J Clin Endocrinol Metab 2007; 92:3697-3704
22. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003; 22:476-485.
23. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14:143-149.
24. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9:635-639.
25. Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, et al. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004; 171 (6 Pt 1): 2484-2488.
26. Chung BC, Choo HY, Kim TW, Eom KD, Kwon OS, Suh J, et al. Analysis of anabolic steroids using GC/MS with selected ion monitoring. J Anal Toxicol 1990; 14:91-95.
27. Chouinard S, Pelletier G, Belanger A, Barbier O. Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 2006; 147:5431-5442.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
29. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol 1993; 44:179-189.
30. Kicman AT, Brooks RV, Collyer SC, Cowan DA, Nanjee MN, Southan GJ, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990; 24:253-264.
31. Palonek E, Gottlieb C, Garle M, Bjorkhem I, Carlstrom K. Serum and urinary markers of exogenous testosterone administration. J Steroid Biochem Mol Biol 1995; 55:121-127.
32. Borts DJ, Bowers LD. Direct measurement of urinary testosterone and epitestosterone conjugates using high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2000; 35:50-61.
33. Heracek J, Richard H, Martin H, Luboslav S, Jana S, Jitka K, et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 2007; 72:375-380.
34. Starka L, Bicikova M, Hampl R. Epitestosterone-an endogenous antiandrogen? J Steroid Biochem 1989; 33:1019-1021.
35. Choi MH, Yoo YS, Chung BC. Biochemical roles of testosterone and epitestosterone to 5 alpha-reductase as indicators of male-pattern baldness. J Invest Dermatol 2001; 116:57-61.
36. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J 2007 advance online publication, 27 March 2007; doi:10.1038/sj.tpj. 6500449.
37. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15:1473-1478.
38. Olsson M, Lindström S, Häggkvist B, Adami H-O, Bälter K, Stattin P, et al. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 2008; 68:571-575
39. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30:1257-1265.